Clinical Trial Update: A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) [Phase 3]

View source ↗

Summary

A Phase 3 placebo-controlled trial of maralixibat (SHP625) in pediatric progressive familial intrahepatic cholestasis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Familial Intrahepatic Cholestasis

Drugs mentioned

• Maralixibat (maralixibat)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | Status: WITHDRAWN